INAB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:17):

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers...

Stats
Today's Volume	55 218.00
Average Volume	353 269
Market Cap	43.31M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.170 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.000
ATR14	$0.0100 (0.99%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Epperly Corinne	Buy	12 500	Stock Option (right to buy)
2024-02-07	Ho William Tai-wei	Buy	502 000	Employee Stock Option (right to buy)
2024-02-07	Goswami Trishna	Buy	176 000	Employee Stock Option (right to buy)
2024-02-07	Rochlin Kate	Buy	186 000	Employee Stock Option (right to buy)
2024-02-07	Lamb Lawrence	Buy	169 000	Employee Stock Option (right to buy)

INSIDER POWER
24.70
Last 98 transactions
Buy: 9 531 383 \| Sell: 5 834 681

Volume Correlation

Long: -0.04 (neutral)

Short: 0.37 (neutral)

Signal:(52.141) Neutral

IN8bio, Inc. Correlation

10 Most Positive Correlations
PCVX	0.832
DTSS	0.822
IMPL	0.82
SLM	0.816
AFYA	0.815
JAZZ	0.814
AVIR	0.811
PDSB	0.811
LIVN	0.806
GOEV	0.805

10 Most Negative Correlations
PAE	-0.843
RAVN	-0.832
NEO	-0.828
ZGNX	-0.813
SERA	-0.813
PEGA	-0.81
ACVA	-0.81
EBAC	-0.809
ICON	-0.808
TA	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IN8bio, Inc. Correlation - Currency/Commodity

0.64
( weak )

-0.33
( neutral )

0.00
( neutral )

0.54
( weak )

0.00
( neutral )

-0.90
( very strong negative )

IN8bio, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2023
Revenue:	$0
Gross Profit:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2022
Revenue:	$0
Gross Profit:	$-1.10M (0.00 %)
EPS:	$-1.310

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.095

Financial Reports:

No articles found.

IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.